Explore the Global EGFR-Mutated Lung Cancer Treatment Market — analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

EGFR-Mutated Lung Cancer Treatment Market

Key Insight

The egfr-mutated lung cancer treatment market is projected to grow from USD 16.1 billion in 2026 to USD 39.2 billion by 2036, at a CAGR of 9.3%. 3rd-gen TKIs will dominate with a 56.0% market share, while 1st-line therapy will lead the applications segment with a 61.0% share.

January 15, 2026

Anurag Sharma

250 Pages

Cite this Report

EGFR-Mutated Lung Cancer Treatment Market

https://www.futuremarketinsights.com/reports/egfr-mutated-lung-cancer-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

BlackRock
The Vanguard Group
Roche
Takeda

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

EGFR-Mutated Lung Cancer Treatment Market

Key Players

Similar Industry Reports